Trial Profile
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Aug 2019
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; AZD 5069; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 20 Jul 2018 Status changed from active, no longer recruiting to completed.
- 03 Jul 2018 Planned End Date changed from 2 Apr 2018 to 3 Jul 2018.
- 03 Jul 2018 Planned primary completion date changed from 2 Apr 2018 to 3 Jul 2018.